Special Issue

Innovative Drug Strategies in Chronic Disease Management: Addressing Non-Adherence and Improving Therapeutic Outcomes

Message from the Guest Editors

The increasing prevalence of chronic diseases has become one of the most important public health problems worldwide. Chronic diseases are associated with increased medication use and complex drug regimens. High medication use leads to polymedication, which is strongly associated with non-adherence and a reduced quality of life. Meanwhile, non-adherence has negative impacts in relation to clinical outcomes, such as furthering disease progression and increasing mortality, as well as in the form of rising healthcare costs. This Special Issue will showcase innovative research on improving medication adherence, highlighting possible new approaches to developing personalized therapeutic strategies for chronic diseases. For this Special Issue, submissions of original research articles and reviews are welcome. The selected set of manuscripts will be published as a Special Issue of *Pharmaceuticals*.

Guest Editors

Dr. Eduardo Gutiérrez-Abejón

- 1. Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
- Pharmacy Directorate, Castilla y León Health Council, 47007 Valladolid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (Group CB21/13/00051), Carlos III Institute of Health, 28029 Madrid, Spain

Prof. Dr. F. Javier Alvarez

Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain

Deadline for manuscript submissions

26 September 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/235846

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

